Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma

New England Journal of Medicine

Volumn 374, Issue 2, 2016, Pages 135-145

  Linehan, W Marston ^a   Spellman, Paul T ^b   Ricketts, Christopher J ^b   Creighton, Chad J ^b   Fei, Suzanne S ^b   Davis, Caleb ^b   Wheeler, David A ^b   Murray, Bradley A ^b   Schmidt, Laura ^b   Vocke, Cathy D ^b   Peto, Myron ^b   Al Mamun, Abu Amar M ^b   Shinbrot, Eve ^b   Sethi, Anurag ^b   Brooks, Samira ^b   Rathmell, W Kimryn ^b   Brooks, Angela N ^b   Hoadley, Katherine A ^b   Robertson, A Gordon ^b   Brooks, Denise ^b   Bowlby, Reanne ^b   Sadeghi, Sara ^b   Shen, Hui ^b   Weisenberger, Daniel J ^b   Bootwalla, Moiz ^b   Baylin, Stephen B ^b   Laird, Peter W ^b   Cherniack, Andrew D ^b   Saksena, Gordon ^b   Haake, Scott ^b   Li, Jun ^b   Liang, Han ^b   Lu, Yiling ^b   Mills, Gordon B ^b   Akbani, Rehan ^b   Leiserson, Mark D M ^b   Raphael, Benjamin J ^b   Anur, Pavana ^b   Bottaro, Donald ^b   Albiges, Laurence ^b   Barnabas, Nandita ^b   Choueiri, Toni K ^b   Czerniak, Bogdan ^b   Godwin, Andrew K ^b   Hakimi, A Ari ^b   Ho, Thai H ^b   Hsieh, James ^b   Ittmann, Michael ^b   Kim, William Y ^b   Krishnan, Bhavani ^b   Merino, Maria J ^b   Shaw, Kenna R Mills ^b   Reuter, Victor E ^b   Reznik, Ed ^b   Shelley, Carl S ^b   Shuch, Brian ^b   Signoretti, Sabina ^b   Srinivasan, Ramaprasad ^b   Tamboli, Pheroze ^b   Thomas, George ^b   Tickoo, Satish ^b   Burnett, Kenneth ^b   Crain, Daniel ^b   Gardner, Johanna ^b   Lau, Kevin ^b   Mallery, David ^b   Morris, Scott ^b   Paulauskis, Joseph D ^b   Penny, Robert J ^b   Shelton, Candace ^b   Shelton, W Troy ^b   Sherman, Mark ^b   Thompson, Eric ^b   Yena, Peggy ^b   Avedon, Melissa T ^b   Bowen, Jay ^b   Gastier Foster, Julie M ^b   Gerken, Mark ^b   Leraas, Kristen M ^b   Lichtenberg, Tara M ^b   Ramirez, Nilsa C ^b   Santos, Tracie ^b   Wise, Lisa ^b   Zmuda, Erik ^b   Demchok, John A ^b   Felau, Ina ^b   Hutter, Carolyn M ^b   Sheth, Margi ^b   Sofia, Heidi J ^b   Tarnuzzer, Roy ^b   Wang, Zhining ^b   Yang, Liming ^b   Zenklusen, Jean C ^b   Zhang, Jiashan ^b   Ayala, Brenda ^b   Baboud, Julien ^b   Chudamani, Sudha ^b   Liu, Jia ^b   Lolla, Laxmi ^b   Naresh, Rashi ^b   Pihl, Todd ^b   Sun, Qiang ^b   Wan, Yunhu ^b   Wu, Ye ^b   Ally, Adrian ^b   Balasundaram, Miruna ^b   Balu, Saianand ^b   Beroukhim, Rameen ^b   Bodenheimer, Tom ^b   Buhay, Christian ^b   Butterfield, Yaron S N ^b   Carlsen, Rebecca ^b   Carter, Scott L ^b   Chao, Hsu ^b   Chuah, Eric ^b   Clarke, Amanda ^b   Covington, Kyle R ^b   Dahdouli, Mahmoud ^b   Dewal, Ninad ^b   Dhalla, Noreen ^b   Doddapaneni, Harsha V ^b   Drummond, Jennifer A ^b   Gabriel, Stacey B ^b   Gibbs, Richard A ^b   Guin, Ranabir ^b   Hale, Walker ^b   Hawes, Alicia ^b   Hayes, D Neil ^b   Holt, Robert A ^b   Hoyle, Alan P ^b   Jefferys, Stuart R ^b   Jones, Steven J M ^b   Jones, Corbin D ^b   Kalra, Divya ^b   Kovar, Christie ^b   Lewis, Lora ^b   Li, Jie ^b   Ma, Yussanne ^b   Marra, Marco A ^b   Mayo, Michael ^b   Meng, Shaowu ^b   Meyerson, Matthew ^b   Mieczkowski, Piotr A ^b   Moore, Richard A ^b   Morton, Donna ^b   Mose, Lisle E ^b   Mungall, Andrew J ^b   Muzny, Donna ^b   Parker, Joel S ^b   Perou, Charles M ^b   Roach, Jeffrey ^b   Schein, Jacqueline E ^b   Schumacher, Steven E ^b   Shi, Yan ^b   Simons, Janae V ^b   Sipahimalani, Payal ^b   Skelly, Tara ^b   Soloway, Matthew G ^b   Sougnez, Carrie ^b   Tam, Angela ^b   Tan, Donghui ^b   Thiessen, Nina ^b   Veluvolu, Umadevi ^b   Wang, Min ^b   Wilkerson, Matthew D ^b   Wong, Tina ^b   Wu, Junyuan ^b   Xi, Liu ^b   Zhou, Jane ^b   Bedford, Jason ^b   Chen, Fengju ^b   Fu, Yao ^b   Gerstein, Mark ^b   Haussler, David ^b   Kasaian, Katayoon ^b   Lai, Phillip ^b   Ling, Shiyun ^b   Radenbaugh, Amie ^b   Van Den Berg, David ^b   Weinstein, John N ^b   Zhu, Jingchun ^b   Albert, Monique ^b   Alexopoulou, Iakovina ^b   Andersen, Jeremiah J ^b   Auman, J Todd ^b   Bartlett, John ^b   Bastacky, Sheldon ^b   Bergsten, Julie ^b   Blute, Michael L ^b   Boice, Lori ^b   Bollag, Roni J ^b   Boyd, Jeff ^b   Castle, Erik ^b   Chen, Ying Bei ^b   Cheville, John C ^b   Curley, Erin ^b   Davies, Benjamin ^b   DeVolk, April ^b   Dhir, Rajiv ^b   Dike, Laura ^b   Eckman, John ^b   Engel, Jay ^b   Harr, Jodi ^b   Hrebinko, Ronald ^b   Huang, Mei ^b   Huelsenbeck Dill, Lori ^b   Iacocca, Mary ^b   Jacobs, Bruce ^b   Lobis, Michael ^b   Maranchie, Jodi K ^b   McMeekin, Scott ^b   Myers, Jerome ^b   Nelson, Joel ^b   Parfitt, Jeremy ^b   Parwani, Anil ^b   Petrelli, Nicholas ^b   Rabeno, Brenda ^b   Roy, Somak ^b   Salner, Andrew L ^b   Slaton, Joel ^b   Stanton, Melissa ^b   Thompson, R Houston ^b   Thorne, Leigh ^b   Tucker, Kelinda ^b   Weinberger, Paul M ^b   Winemiller, Cynthia ^b   Zach, Leigh Anne ^b   Zuna, Rosemary ^b   more..

^a NATIONAL CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FUMARATE HYDRATASE; TRANSCRIPTION FACTOR NRF2; MESSENGER RNA; MET PROTEIN, HUMAN; MICRORNA; NFE2L2 PROTEIN, HUMAN; RNA; SCATTER FACTOR RECEPTOR;

ADULT; ARTICLE; CANCER CLASSIFICATION; CANCER GENETICS; CANCER PROGNOSIS; CANCER SURVIVAL; CDKN2A GENE; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; EXOME; GENE; GENE LOSS; GENE MUTATION; GENE SILENCING; GENETIC ANALYSIS; GENETIC CODE; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MOLECULAR GENETICS; PAPILLARY CARCINOMA; PHENOTYPE; PRIORITY JOURNAL; PROTEOMICS; SEQUENCE ANALYSIS; SETD2 GENE; SINGLE NUCLEOTIDE POLYMORPHISM; TFE3 GENE; CHEMISTRY; GENETICS; KIDNEY TUMOR; METABOLISM; MUTATION; PHYSIOLOGY; SIGNAL TRANSDUCTION;

CARCINOMA, PAPILLARY; CPG ISLANDS; DNA METHYLATION; HUMANS; KIDNEY NEOPLASMS; MICRORNAS; MUTATION; NF-E2-RELATED FACTOR 2; PHENOTYPE; PROTO-ONCOGENE PROTEINS C-MET; RNA, MESSENGER; RNA, NEOPLASM; SEQUENCE ANALYSIS, RNA; SIGNAL TRANSDUCTION;

EID: 84954286974     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1505917     Document Type: Article

References (39)

1. Linehan WM, Srinivasan R, Schmidt LS. The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol 2010; 7: 277-85.
2. Linehan WM. Genetic basis of kidney cancer: role of genomics for the development of disease-based therapeutics. Genome Res 2012; 22: 2089-100.
3. Delahunt B, Eble JN. Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors. Mod Pathol 1997; 10: 537-44.
4. Zbar B, Tory K, Merino MJ, et al. Hereditary papillary renal cell carcinoma. J Urol 1994; 151: 561-6.
5. Schmidt LS, Duh FM, Chen F, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET protooncogene in papillary renal carcinomas. Nat Genet 1997; 16: 68-73.
6. Schmidt LS, Junker K, Nakaigawa N, et al. Novel mutations of the MET protooncogene in papillary renal carcinomas. Oncogene 1999; 18: 2343-50.
7. Durinck S, Stawiski EW, Pavía-Jiménez A, et al. Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes. Nat Genet 2015; 47: 13-21.
8. Launonen V, Vierimaa O, Kiuru M, et al. Inherited susceptibility to uterine leiomyomas and renal cell cancer. Proc Natl Acad Sci U S A 2001; 98: 3387-92.
9. Grubb RL III, Franks ME, Toro J, et al. Hereditary leiomyomatosis and renal cell cancer: a syndrome associated with an aggressive form of inherited renal cancer. J Urol 2007; 177: 2074-9.
10. Tomlinson IP, Alam NA, Rowan AJ, et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 2002; 30: 406-10.
11. Sudarshan S, Sourbier C, Kong HS, et al. Fumarate hydratase deficiency in renal cancer induces glycolytic addiction and HIF-1 alpha stabilization by glucose-dependent generation of reactive oxygen species. Mol Cell Biol 2009; 15: 4080-90.
12. Ooi A, Wong JC, Petillo D, et al. An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma. Cancer Cell 2011; 20: 511-23.
13. Ooi A, Dykema K, Ansari A, et al. CUL3 and NRF2 mutations confer an NRF2 activation phenotype in a sporadic form of papillary renal cell carcinoma. Cancer Res 2013; 73: 2044-51.
14. Jiang F, Richter J, Schraml P, et al. Chromosomal imbalances in papillary renal cell carcinoma: genetic differences between histological subtypes. Am J Pathol 1998; 153: 1467-73.
15. Lawrence MS, Stojanov P, Mermel CH, et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 2014; 505: 495-501.
16. Kauffman EC, Ricketts CJ, Rais-Bahrami S, et al. Molecular genetics and cellular features of TFE3 and TFEB fusion kidney cancers. Nat Rev Urol 2014; 11: 465-75.
17. Schmidt LS, Junker K, Weirich G, et al. Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET protooncogene. Cancer Res 1998; 58: 1719-22.
18. Boezio AA, Berry L, Albrecht BK, et al. Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors. Bioorg Med Chem Lett 2009; 19: 6307-12.
19. Muratani M, Deng N, Ooi WF, et al. Nanoscale chromatin profiling of gastric adenocarcinoma reveals cancer-Associated cryptic promoters and somatically acquired regulatory elements. Nat Commun 2014; 5: 4361.
20. Gan HK, Cvrljevic AN, Johns TG. The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered. FEBS J 2013; 280: 5350-70.
21. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013; 499: 43-9.
22. Shen H, Laird PW. Interplay between the cancer genome and epigenome. Cell 2013; 153: 38-55.
23. Whitfield ML, Sherlock G, Saldanha AJ, et al. Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Mol Biol Cell 2002; 13: 1977-2000.
24. Harris AL. Hypoxia-A key regulatory factor in tumour growth. Nat Rev Cancer 2002; 2: 38-47.
25. Tong WH, Sourbier C, Kovtunovych G, et al. The glycolytic shift in fumaratehydratase-deficient kidney cancer lowers AMPK levels, increases anabolic propensities and lowers cellular iron levels. Cancer Cell 2011; 20: 315-27.
26. Yang Y, Lane AN, Ricketts CJ, et al. Metabolic reprogramming for producing energy and reducing power in fumarate hydratase null cells from hereditary leiomyomatosis renal cell carcinoma. PLoS One 2013; 8(8): e72179.
27. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490: 61-70.
28. Hoadley KA, Yau C, Wolf DM, et al. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell 2014; 158: 929-44.
29. Venugopal R, Jaiswal AK. Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NAD(P)H:quinone oxidoreductase1 gene. Proc Natl Acad Sci U S A 1996; 93: 14960-5.
30. Kovac M, Navas C, Horswell S, et al. Recurrent chromosomal gains and heterogeneous driver mutations characterise papillary renal cancer evolution. Nat Commun 2015; 6: 6336.
31. Noushmehr H, Weisenberger DJ, Diefes K, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2010; 17: 510-22.
32. Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014; 511: 543-50.
33. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014; 513: 202-9.
34. Linehan WM, Rouault TA. Molecular pathways: fumarate hydratase-deficient kidney cancer-targeting the Warburg effect in cancer. Clin Cancer Res 2013; 19: 3345-52.
35. Xiao M, Yang H, Xu W, et al. Inhibition of ?-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors. Genes Dev 2012; 26: 1326-38.
36. Choueiri TK, Vaishampayan U, Rosenberg JE, et al. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol 2013; 31: 181-6.
37. Johnson R, Halder G. The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment. Nat Rev Drug Discov 2014; 13: 63-79.
38. Sporn MB, Liby KT. NRF2 and cancer: the good, the bad and the importance of context. Nat Rev Cancer 2012; 12: 564-71.
39. Sourbier C, Ricketts CJ, Matsumoto S, et al. Targeting ABL1-mediated oxidative stress adaptation in fumarate hydratasedeficient cancer. Cancer Cell 2014; 26: 840-50.